Register
Exterior AbbVie sign in front of a metal security fence and industrial building during winter conditions

PARTNERSHIPS

23 Jun 2026

Why AbbVie Just Spent $10.9B on Apogee

AbbVie agreed to acquire Apogee Therapeutics for $10.9B, adding late-stage IL-13 and TSLP assets targeting atopic dermatitis and asthma

Intellia Therapeutics sign on an orange glass wall at a corporate entrance with a bright modern lobby beyond

INSIGHTS

22 Jun 2026

Intellia Takes Its CRISPR HAE Fix to the FDA

Intellia has begun a rolling FDA BLA submission for lonvo-z after Phase 3 success, targeting a potential H1 2027 launch

FDA and US Department of Health and Human Services sign outside the Food and Drug Administration headquarters

RESEARCH

19 Jun 2026

Stop Repeating Yourself, FDA Tells Sponsors

FDA draft guidance lets sponsors use prior knowledge in genome-editing submissions, aiming to accelerate cell and gene therapies for rare ...

Hands sorting packaged medications in a pharmacy drawer with labelled drug boxes arranged in compartments

REGULATORY

18 Jun 2026

Tiered Exclusivity Puts Rare Disease Deals at Stake

EU's 2026 Pharmaceutical Reform introduces tiered orphan drug exclusivity, diverging sharply from U.S. policy and adding new supply obliga...

Novartis headquarters building showing the company logo on the upper facade and a second sign on the side

PARTNERSHIPS

16 Jun 2026

A $1.4B Vote of Confidence for Molecular Glue

Novartis commits $40M upfront in a second molecular glue collaboration with Orionis Biosciences worth up to $1.4 billion

Man holding a commemorative glass at a Nasdaq podium beneath the Parabilis Medicines logo backdrop

INVESTMENT

15 Jun 2026

The Biggest Biotech IPO of 2026 Has a Name

Parabilis Medicines raised $770.5M in the biggest biotech IPO of 2026, backed by a Regeneron private placement deal

topics on the agenda

A RADICALLY NEW ERA OF PATIENT-DRIVEN THERAPEUTICS

Day 1: MONDAY, JULY 13, 2026

09:00 - 09:25

DESIGNED WITH PATIENTS, FOR PATIENTS: RISE UP SICKLE CELL DISEASE CLINICAL PROGRAM

Day 1: MONDAY, JULY 13, 2026

09:30 - 09:55

PANEL DISCUSSION ON PATIENT ADVOCACY AS INFRASTRUCTURE FOR RARE DISEASE DEVELOPMENT

Day 1: MONDAY, JULY 13, 2026

11:00 - 11:30

View more topics

SUBSCRIBE FOR UPDATES

By submitting, you agree to receive email communications from the event organizers, including upcoming promotions and discounted tickets, news, and access to related events.